In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding

Area of Science:

• Cardiology
• Hematology
• Thrombosis Research

Background:

• Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disorder requiring long-term anticoagulation.
• Traditional anticoagulation therapy involves vitamin K antagonists (VKAs), which necessitate regular monitoring.
• Direct oral anticoagulants (DOACs) offer a potential alternative with fixed dosing and less monitoring.

Purpose of the Study:

• To compare the efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with antiphospholipid syndrome (APS).
• To synthesize evidence from randomized controlled trials (RCTs) to inform clinical practice guidelines for APS management.

Main Methods:

• Systematic meta-analysis of randomized controlled trials (RCTs) comparing DOACs with VKAs in patients diagnosed with APS.
• Inclusion criteria focused on studies reporting thrombotic events, major bleeding, and other relevant clinical outcomes.
• Statistical methods were employed to pool data and assess treatment effects.

Main Results:

• Direct oral anticoagulants demonstrated non-inferior efficacy in preventing thrombotic events compared to vitamin K antagonists.
• The incidence of major bleeding events was comparable between patients treated with DOACs and those on VKAs.
• No significant differences were observed in other safety outcomes between the two anticoagulant classes.

Conclusions:

• Direct oral anticoagulants represent a viable and safe alternative to vitamin K antagonists for long-term anticoagulation in patients with antiphospholipid syndrome.
• These findings support the potential integration of DOACs into clinical guidelines for APS management, offering convenience and potentially improved patient adherence.